Form 4: Casdin Entities Boost Stake in Standard BioTools

Casdin Partners Master Fund and related entities increased their beneficial ownership in Standard BioTools Inc. through recent stock purchases.

Summary

• Casdin Partners Master Fund, L.P. and affiliated entities acquired a total of 350,000 shares of Standard BioTools Inc. common stock.
• Purchases occurred on December 2, 2025 (125,000 shares at a weighted average price of $1.4201), December 3, 2025 (75,000 shares at a weighted average price of $1.4405), and December 4, 2025 (150,000 shares at a weighted average price of $1.4468).
• Following these transactions, Casdin Partners Master Fund, L.P. indirectly beneficially owns 72,100,000 shares.
• Eli Casdin directly owns 2,901,062 shares.
• Casdin Private Growth Equity Fund II, L.P. indirectly owns 13,939,637 shares.
• Casdin Private Growth Equity Fund, L.P. indirectly owns 2,744,219 shares.
• Eli Casdin, as managing member of Casdin Capital, LLC and Casdin Partners GP, LLC, and general partner of various funds, is deemed to indirectly beneficially own shares held by these entities.
• Eli Casdin is deputized to represent the reporting persons on the board of directors of Standard BioTools Inc., making all reporting persons directors by deputization for Section 16 purposes.

Sentiment

Score: 8

Explanation: The substantial insider buying by a major institutional investor and director, Eli Casdin, signals strong confidence in Standard BioTools Inc. at the current valuation. This is a positive indicator for the company's future prospects.

Positives

• Significant insider buying by a 10% owner and director, indicating confidence in the company's future prospects.
• The purchases occurred at prices ranging from $1.4050 to $1.4588, suggesting a belief in value at these levels.
• Increased alignment of interests between a major institutional investor/director and other shareholders.

Future Outlook

NA

Industry Context

This insider buying activity by a significant institutional investor and director in a biotechnology tools company like Standard BioTools Inc. could signal confidence in the company's strategic direction or upcoming developments within the life sciences sector. Such moves are often watched closely by the market as indicators of potential future performance, especially in growth-oriented industries.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisitions of common stock by Casdin Partners Master Fund, L.P. and its affiliated entities, including those where Eli Casdin is the managing member, represent transactions between related parties (10% owner, director by deputization, and their associated funds) and the issuer.

Stakeholder Impact

• Shareholders: Increased confidence due to significant insider buying by a major investor and director, potentially signaling undervaluation or positive future developments.
• Management: Stronger alignment with a key institutional investor and board member.

Key Dates

Recommendation

The substantial insider buying by Casdin Partners Master Fund, L.P. and its affiliates, including Eli Casdin who serves as a director by deputization and a 10% owner, is a strong bullish signal. Insiders typically buy shares when they believe the stock is undervalued or expect significant positive developments. This increased stake at current price levels suggests high confidence in Standard BioTools Inc.'s future performance, making it an attractive 'buy' for investors.

Keywords

STANDARD BIOTOOLS, LAB, Casdin Partners, Insider Buying, Form 4, Equity Acquisition, 10% Owner, Director by Deputization, Stock Purchase, Beneficial Ownership